- Home
- BMY vs NEM Comparison
BMY vs NEM Comparison
Compare BMY & NEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMY
- NEM
- Stock Information
- Founded
- BMY 1887
- NEM 1916
- Country
- BMY United States
- NEM United States
- Employees
- BMY N/A
- NEM N/A
- Industry
- BMY Biotechnology: Pharmaceutical Preparations
- NEM Precious Metals
- Sector
- BMY Health Care
- NEM Basic Materials
- Exchange
- BMY Nasdaq
- NEM Nasdaq
- Market Cap
- BMY 94.0B
- NEM 93.0B
- IPO Year
- BMY N/A
- NEM N/A
- Fundamental
- Price
- BMY $43.68
- NEM $80.38
- Analyst Decision
- BMY Hold
- NEM Buy
- Analyst Count
- BMY 14
- NEM 11
- Target Price
- BMY $57.54
- NEM $97.17
- AVG Volume (30 Days)
- BMY 15.5M
- NEM 12.9M
- Earning Date
- BMY 10-30-2025
- NEM 10-23-2025
- Dividend Yield
- BMY 5.82%
- NEM 1.25%
- EPS Growth
- BMY N/A
- NEM N/A
- EPS
- BMY 2.49
- NEM 6.43
- Revenue
- BMY $47,704,000,000.00
- NEM $21,503,000,000.00
- Revenue This Year
- BMY N/A
- NEM $15.26
- Revenue Next Year
- BMY N/A
- NEM $5.48
- P/E Ratio
- BMY $17.14
- NEM $12.39
- Revenue Growth
- BMY 2.57
- NEM 26.59
- 52 Week Low
- BMY $42.52
- NEM $36.86
- 52 Week High
- BMY $63.33
- NEM $98.58
- Technical
- Relative Strength Index (RSI)
- BMY 45.50
- NEM 43.42
- Support Level
- BMY $42.52
- NEM $76.05
- Resistance Level
- BMY $45.23
- NEM $81.84
- Average True Range (ATR)
- BMY 0.68
- NEM 3.46
- MACD
- BMY -0.00
- NEM -1.77
- Stochastic Oscillator
- BMY 42.88
- NEM 19.23
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
About NEM Newmont Corporation
Newmont is the world's largest gold miner. It bought Goldcorp in 2019, combined its Nevada mines in a joint venture with competitor Barrick later that year, and also purchased competitor Newcrest in November 2023. Its portfolio includes 17 wholly or majority owned mines and interests in two joint ventures in the Americas, Africa, Australia and Papua New Guinea. The company is expected to sell roughly 5.6 million ounces of gold in 2025 from its core mines after selling six higher-cost, smaller mines. Newmont also produces material amounts of copper, silver, zinc, and lead as byproducts. It had about two decades of gold reserves along with significant byproduct reserves at the end of December 2024.